Medical Devices & Tech

CorInnova Incorporated

7000 Fannin St., Suite 1950-D
Houston, TX 77030 USA
Click for website

Research Sector Medical Devices & Tech

Summary Description Develops cardiological devices.

Management William Altman, President & CEO; John Criscione M.D., Ph.D. Founder & Chief Technology Officer; Dennis Robbins, Ph.D., Founder & Director; William Cohn, MD, Clinical Advisory Board (Texas Heart Institute); Boris Leschinsky, Clinical Advisory Board (former VP, Datascope)

Click here for Financial Data
Keywords: Medical Device, Cardiology, Congestive Heart Failure, Cardiac Rehabilitation, Cardiac Rekinesis Therapy, Cardiac Assist, Circulatory Support, Cardiac Recovery, Cardiac, Direct Cardiac Compression Device


Updated: Oct. 22, 2015


CorInnova is has developed a breakthrough technological platform for the treatment of heart failure. Congestive heart failure is a gradually progressive condition in which the heart muscle weakens, le......view more

Products / Services

The first product, CardiacSTAR, is an inflatable girdle that surrounds both ventricles of the heart. Air inflates the device in synchrony with the heart and increases cardiac output by squeezing the ......view more

Technology / Differentiation

Unlike prior direct cardiac compression devices, CorInnova's technology does not invert the curvature of the heart. Instead, CorInnova's technology corrects bad cardiac motion and promotes correct ca...view more

Market / Customers

The 230,000 U.S. patients in end-stage congestive heart failure have an extremely poor prognosis (40% two-year mortality), and treatment options are limited. Transplant is the preferred treatment as ......view more

Competitors / Substitutes / Alternatives

Thoratec, the current LVAD leader, has a $2 billion market cap. Heartware, a next generation LVAD competitor with a device pending FDA approval, has a $1 billion market cap, demonstrating investor in...view more


CorInnova plans to use venture financing to fund pre-clinical and clinical development, leading to approval and sales first in Europe and then the U.S. Joint venture agreements with leading medical d...view more

Revenue / Funding

To date, funding has been provided by approximately $1 M in US NIH and US NSF SBIR/STTR grants and $1.5 M from investors....view more